<DOC>
	<DOCNO>NCT01344070</DOCNO>
	<brief_summary>Generic formulation prescription drug , relatively low cost , improve healthcare long maintain registration-quality public trust . On hand , market availability several generic formulation raise concern regard interchangeability , despite prove individually therapeutically interchangeable correspond innovator formulation . The investigator propose assess quality therapeutic interchangeability generic formulation drug market Saudi Arabia , use fifteen , commonly-used , oral , solid , immediate-release , non-combinational drug .</brief_summary>
	<brief_title>Generic Formulations Commonly-used Oral Drugs Saudi Arabia : Interchangeability &amp; Post-marketing Quality</brief_title>
	<detailed_description>Generic formulation prescription drug , relatively low cost , improve healthcare long maintain registration-quality public trust . On hand , market availability several generic formulation raise concern regard interchangeability , despite prove individually therapeutically interchangeable correspond innovator formulation . The investigator propose assess quality therapeutic interchangeability generic formulation drug market Saudi Arabia , use fifteen , commonly-used , oral , solid , immediate-release , non-combinational drug . The following drug identify Saudi National Formulary ( September 2006 ) , among oral , immediate-release , non-combinational drug , high number formulation ( 15 47 ) : ciprofloxacin , ranitidine , amoxicillin , paracetamol , atenolol , cephalexin , ibuprofen , diclofenac , metformin , omeprazole , metronidazole , enalapril , clarithromycin , amlodipine , fluconazole . In first set study drug , four-treatment , four-period , four-sequence , crossover bioequivalence study conduct innovator three randomly-selected generic formulation . Each study design power 0.9 detect bioequivalence , sample wash-out period least 5 7 half life , respectively . Individuals identify first set study large intra-subject variation ( bioequivalence parameter ratios less 80 % 120 % AUC ) subject second set study , 2 batch reference formulation ( include batch use first set study ) generic formulation compare two-treatment , four-period , two-sequence , replicate design crossover bioequivalence study . Drug level determine HPLC LC-MS-MS method , locally-validated accord international guideline . After log transformation , AUC Cmax ( non-compartmental model ) formulation compare pair-wise ANOVA . Pair-wise bioequivalence test 90 % ( 95 % ) confidence interval ratio Schuirmann 's two one side t-tests 70-143 , 80-125 % , 90-112 % range . The following determine : 1 ) prevalence generic formulation bioequivalent innovator formulation , 2 ) prevalence phenomena two generic innovator formulation bioequivalent , 3 ) percentage individual large intra-subject variation despite presence average bioequivalence two formulation , 4 ) much large intra-subject variation 3 true relate , part , product failure , random error , subject-by-formulation interaction ; compare intra-subject variability two batch innovator formulation compare .</detailed_description>
	<criteria>No evidence clinically important deviation normal health indicate recent physical examination , medical history , clinical laboratory test ( complete blood count , renal hepatic profile , routine urinalysis . Body Mass Index ( BMI ) less 35 kg/m2 . Acceptance abstain take medication ( include overthecounter [ OTC ] drug ) least 2 week prior , study ; smoke take alcohol caffeine relate xanthenescontaining beverage food 48 hour take study drug throughout two blood sample period . contraindication use drug . history hypersensitivity drug test related compound .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>innovator formulation</keyword>
	<keyword>generic formulation</keyword>
	<keyword>bioequivalence</keyword>
	<keyword>interchangeability</keyword>
	<keyword>inter-patch variation</keyword>
	<keyword>quality generic drug formulation market</keyword>
	<keyword>Interchangeability market generic formulation</keyword>
	<keyword>prevalence large intrasubject variability despite average bioequivalence</keyword>
	<keyword>Causes large intrasubject variability</keyword>
</DOC>